Effect of Levosimendan Treatment in Pediatric Patients With Cardiac Dysfunction: An Update of a Systematic Review and Meta-Analysis of Randomized Controlled Trials
| Autor: | Simona Silvetti, Alessandro Belletti, Stefania Bianzina, Mona Momeni |
|---|---|
| Přispěvatelé: | UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Service d'anesthésiologie |
| Rok vydání: | 2022 |
| Předmět: |
medicine.medical_specialty
Cardiotonic Agents Adolescent Cardiac Output Low heart failure Hemodynamics Cardiac dysfunction law.invention levosimendan children Randomized controlled trial law Acute care medicine Humans Child Intensive care medicine Simendan Randomized Controlled Trials as Topic simdax business.industry Hydrazones Levosimendan medicine.disease Cardiac surgery Pyridazines Anesthesiology and Pain Medicine Heart failure Meta-analysis Cardiology and Cardiovascular Medicine business cardiac surgery medicine.drug |
| Zdroj: | Journal of cardiothoracic and vascular anesthesia, Vol. 36, no.3, p. 657-664 (2022) |
| ISSN: | 1053-0770 |
| DOI: | 10.1053/j.jvca.2021.09.018 |
| Popis: | Levosimendan increasingly has been used to treat heart failure and cardiac dysfunction in pediatric patients. Currently, there is only limited evidence that this drug positively affects outcomes. The authors' aim was to investigate the effects of levosimendan on hemodynamic parameters and outcomes in pediatric patients in all clinical settings. The study design was a systematic review of randomized and nonrandomized studies. Randomized clinical trials (RCTs) were included in a meta-analysis. The primary outcome of the meta-analysis was the effect of levosimendan on central venous oxygen saturation (ScvO) and lactate values as surrogate markers of low-cardiac-output syndrome. The study setting was any acute care setting. Study participants were pediatric patients (age |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect